3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Neuroendocrine Tumors
5
Carcinoma, Hepatocellular
5
Stomach Neoplasms
4
Esophageal Neoplasms
4
Weight Loss
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Breast Neoplasms
3
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Malnutrition
2
Intestinal Obstruction
2
Duodenal Neoplasms
2
Diarrhea
2
Colorectal Neoplasms
2
Carcinoid Tumor
2
Adenoma, Islet Cell
2
Acromegaly
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vomiting
1
Vipoma
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Somatostatinoma
1
Serotonin Syndrome
1
Sarcoma
1
Rectal Neoplasms
1
Interventions
lutetium Lu 177 dotatate
5
copper dotatate CU-64
3
Magnetic Resonance Spectroscopy
3
lanreotide
2
gallium Ga 68 dotatate
2
Nivolumab
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
Carboplatin
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
pasireotide
1
irinotecan sucrosofate
1
folfirinox
1
cabozantinib
1
abemaciclib
1
X-Rays
1
Temozolomide
1
Somatostatin
1
Resveratrol
1
Radiosurgery
1
Octreotide
1
Ipilimumab
1
Granulocyte Colony-Stimulating Factor
1
Fluorodeoxyglucose F18
1
Filgrastim
1
Etoposide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gastro-enteropancreatic neuroendocrine tumor
×
Octreotide
×
Clear all
NCT05701241
2024-06-14
SAUNA
University Hospital, Antwerp
Phase 4
Recruiting
270 enrolled